

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Oncology*

**Manuscript NO:** 73633

**Title:** Commentary: Evaluating Potential Glioma Serum Biomarkers, with Future Applications

**Provenance and peer review:** Unsolicited manuscript; externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05196023

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Surgical Oncologist

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** United States

**Manuscript submission date:** 2021-11-28

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-12-12 04:29

**Reviewer performed review:** 2021-12-23 02:36

**Review time:** 10 Days and 22 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="radio"/> ] Anonymous [ <input type="radio"/> ] Onymous
	Conflicts-of-Interest: [ <input type="radio"/> ] Yes [ <input checked="" type="radio"/> ] No

## SPECIFIC COMMENTS TO AUTHORS

In this work, the authors mainly compared Gandhi et al.'s work with previous related literatures, pointing out the similar and controversial results with their predictive panel of four immune markers. The authors also suggested a new application for the panel and proposed the potentially important marker that may promote Gandhi et al.'s work. However, there exists some concerns in this manuscript. Most of the similar and controversial results from previous literatures proposed in this manuscript have been discussed in Gandhi et al.'s article. For example, Gandhi et al. have discussed Adams et al.'s and Zhai et al.'s studies focused on kynurenine and attributed the contradict between their studies to the small number of patients. Therefore, they performed the analysis based on a relatively larger cohort. The previous literatures the authors mentioned in the manuscript were mainly based on glioblastomas, while most of the patients in Gandhi et al.'s study were astrocytic and oligo-component, which have different biological behaviors with glioblastomas. Besides, one of the applications for Gandhi et al.'s panel is to differentiate patients of the IDH wt/mut status. The authors may need to supply related literatures to give a comprehensive comment to Gandhi et al.'s work. The new application the authors suggested for Gandhi et al.'s panel to differentiate tumor progression from radiation necrosis and the potentially important molecules IL-33 they proposed may be meaningful promotion for Gandhi et al.'s work. But these hypotheses still lack statistical data to support. The title of the manuscript may need to be more specific.

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Oncology*

**Manuscript NO:** 73633

**Title:** Commentary: Evaluating Potential Glioma Serum Biomarkers, with Future Applications

**Provenance and peer review:** Unsolicited manuscript; externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 02841837

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** United States

**Manuscript submission date:** 2021-11-28

**Reviewer chosen by:** Ze-Mao Gong

**Reviewer accepted review:** 2022-01-27 13:37

**Reviewer performed review:** 2022-02-01 13:41

**Review time:** 5 Days

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="checkbox"/> ] Anonymous [ <input type="checkbox"/> ] Onymous Conflicts-of-Interest: [ <input type="checkbox"/> ] Yes [ <input checked="" type="checkbox"/> ] No
-------------------------------------	---

#### **SPECIFIC COMMENTS TO AUTHORS**

none.